The addition of trastuzumab resulted in significantly higher levels of tumour apoptosis and combined apoptosis/necrosis in HER2 + tumours compared to TNBC and Luminal A tumours (Fig. 6C). The gene discussed is ERBB2; the disease is neoplasm.